Phase 1 Evaluation of Elezanumab (Anti–Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants

OBJECTIVE: This study was undertaken to describe the safety, tolerability, pharmacokinetics, and immunogenicity of elezanumab (ABT‐555), a fully human monoclonal antibody (mAb) directed against repulsive guidance molecule A (RGMa), in healthy and multiple sclerosis (MS) study participants. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalluri, Hari V., Rosebraugh, Matthew R., Misko, Thomas P., Ziemann, Adam, Liu, Wei, Cree, Bruce A. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100020/
https://www.ncbi.nlm.nih.gov/pubmed/36093738
http://dx.doi.org/10.1002/ana.26503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100020/
https://www.ncbi.nlm.nih.gov/pubmed/36093738
http://dx.doi.org/10.1002/ana.26503

Ejemplares similares